Patent · US Active

Carrier for targeting nerve cells

US10883096B2 · kind B2 · utility

7Cited by

30References

8Claims

0Family size

Assignee

IPSEN BIOINNOVATION LIMITED · GB

Inventors

Andreas Rummel · Hannover, DE
Tanja Weil · Frankfurt am Main, DE
Aleksandrs Gutcaits · Rīga, LV

Key dates

Filing date	Dec 14, 2018
Grant date	Jan 5, 2021
Priority date	—
Expiry date	Dec 14, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.